Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYNR-CS in anoxic brain injury
NCT02210624Unknown
- Start
- Mar 2013
- Primary completion
- Dec 2018
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Open-label trial of lenzumestrocel in anoxic brain injury (ABI). Primary endpoint: Safety assessment at 7 weeks. Status: unknown.
02
Drugs
lenzumestrocel
03
Conditions
anoxic brain injury (ABI)
Beyond the preview
Go deeper on NCT02210624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210624.